Literature DB >> 25445636

Blood and marrow transplant clinical trials network state of the Science Symposium 2014.

Frederick R Appelbaum1, Claudio Anasetti2, Joseph H Antin3, Harold Atkins4, Stella Davies5, Steven Devine6, Sergio Giralt7, Helen Heslop8, Ginna Laport9, Stephanie J Lee10, Brent Logan11, Marcelo Pasquini11, Michael Pulsipher12, Edward Stadtmauer13, John R Wingard14, Mary M Horowitz11.   

Abstract

Entities:  

Keywords:  Hematopoietic cell transplantation; Leukemia; Lymphoma; Myeloma

Mesh：

Year:  2014        PMID： 25445636      PMCID： PMC4426907          DOI： 10.1016/j.bbmt.2014.10.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  126 in total

1.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

2.  Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface.

Authors:  M Tomblyn; T Chiller; H Einsele; R Gress; K Sepkowitz; J Storek; J R Wingard; J-A H Young; M J Boeckh
Journal:  Bone Marrow Transplant       Date:  2009-10       Impact factor: 5.483

Review 3.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

4.  National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.

Authors:  Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-14       Impact factor: 5.742

5.  An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients.

Authors:  Margaret Pollack; Judson Heugel; Hu Xie; Wendy Leisenring; Jan Storek; Jo-Anne Young; Manisha Kukreja; Ronald Gress; Marcie Tomblyn; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-10       Impact factor: 5.742

6.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

7.  Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.

Authors:  Elias Jabbour; Sergio Giralt; Hagop Kantarjian; Guillermo Garcia-Manero; Madan Jagasia; Partow Kebriaei; Leandro de Padua; Elizabeth J Shpall; Richard Champlin; Marcos de Lima
Journal:  Cancer       Date:  2009-05-01       Impact factor: 6.860

Review 8.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.

Authors:  Corey Cutler; Pratik Multani; David Robbins; Haesook T Kim; Thuy Le; Jonathan Hoggatt; Louis M Pelus; Caroline Desponts; Yi-Bin Chen; Betsy Rezner; Philippe Armand; John Koreth; Brett Glotzbecker; Vincent T Ho; Edwin Alyea; Marlisa Isom; Grace Kao; Myriam Armant; Leslie Silberstein; Peirong Hu; Robert J Soiffer; David T Scadden; Jerome Ritz; Wolfram Goessling; Trista E North; John Mendlein; Karen Ballen; Leonard I Zon; Joseph H Antin; Daniel D Shoemaker
Journal:  Blood       Date:  2013-08-30       Impact factor: 22.113
View more
  12 in total

1.  Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age.

Authors:  Mohamed L Sorror
Journal:  Leuk Lymphoma       Date:  2015-05-20

Review 2.  Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.

Authors:  M Elsawy; M L Sorror
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

Review 3.  The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-11       Impact factor: 5.742

4.  Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians.

Authors:  William A Wood; Margaret K McGinn; Doug Wilson; Allison M Deal; Nandita Khera; Thomas C Shea; Steven M Devine; Frederick R Appelbaum; Mary M Horowitz; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2016-07-29       Impact factor: 5.742

5.  Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  John E Levine; Joseph H Antin; Carl E Allen; Lauri M Burroughs; Kenneth R Cooke; Steven Devine; Helen Heslop; Ryotaro Nakamura; Julie An Talano; Gregory Yanik; Nancy DiFronzo
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-05       Impact factor: 5.742

Review 6.  Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?

Authors:  Bronwen E Shaw
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

7.  Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Mohamed L Sorror; Brent R Logan; Xiaochun Zhu; J Douglas Rizzo; Kenneth R Cooke; Philip L McCarthy; Vincent T Ho; Mary M Horowitz; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-07       Impact factor: 5.742

8.  Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.

Authors:  Joseph Pidala; Mehdi Hamadani; Peter Dawson; Michael Martens; Amin M Alousi; Madan Jagasia; Yvonne A Efebera; Saurabh Chhabra; Iskra Pusic; Shernan G Holtan; James L M Ferrara; John E Levine; Marco Mielcarek; Claudio Anasetti; Joseph H Antin; Javier Bolaños-Meade; Alan Howard; Brent R Logan; Eric S Leifer; Theresa S Pritchard; Mary M Horowitz; Margaret L MacMillan
Journal:  Blood       Date:  2020-01-09       Impact factor: 22.113

9.  Patient HLA Germline Variation and Transplant Survivorship.

Authors:  Effie W Petersdorf; Philip Stevenson; Mari Malkki; Roland K Strong; Stephen R Spellman; Michael D Haagenson; Mary M Horowitz; Ted Gooley; Tao Wang
Journal:  J Clin Oncol       Date:  2018-06-14       Impact factor: 44.544

Review 10.  Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies.

Authors:  Steven M Devine; Mary M Horowitz
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.